{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T09:32:21Z","timestamp":1786613541814,"version":"build-2736575974"},"reference-count":26,"publisher":"Pensoft Publishers","issue":"4","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FM"],"abstract":"<jats:p>\n                    <jats:bold>Abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Introduction<\/jats:bold>\n                    : Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide and ranks among the top three in Indonesia. Most patients were diagnosed in a locally advanced stage, with a high recurrence rate despite standard oxaliplatin-based chemotherapy. The hypoxic tumor microenvironment through activation of HIF-1\u03b1 and systemic inflammation reflected by the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) could be associated with the tumor progression.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Aim<\/jats:bold>\n                    : To evaluate the association of HIF-1\u03b1 expression, NLR, and PLR with three-year progression-free survival (PFS) in locally advanced CRC patients.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods<\/jats:bold>\n                    : This retrospective cohort study included 50 patients with high-risk stage II and stage III CRC who underwent surgical resection and adjuvant oxaliplatin-based chemotherapy in Cipto Mangunkusumo National Hospital. HIF-1\u03b1 expression was assessed by immunohistochemistry, while NLR and PLR were calculated from pre-treatment blood tests. Data were analyzed using Kaplan\u2013Meier and Cox regression methods, with\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt;0.05 considered statistically significant.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    : The median HIF-1\u03b1 expression was 96.32%, with a cut-off value of 96.51% (AUC 0.472;\n                    <jats:italic>p<\/jats:italic>\n                    =0.746). There was no significant association between HIF-1\u03b1 expression and three-year PFS (HR 1.274;\n                    <jats:italic>p<\/jats:italic>\n                    =0.495). The cut-off points for NLR and PLR were 3.46 (AUC 0.486;\n                    <jats:italic>p<\/jats:italic>\n                    =0.872) and 198.31 (AUC 0.505;\n                    <jats:italic>p<\/jats:italic>\n                    =0.952), respectively, and both were not significantly associated with three-year PFS (NLR: HR 0.947;\n                    <jats:italic>p<\/jats:italic>\n                    =0.874; PLR: HR 1.060;\n                    <jats:italic>p<\/jats:italic>\n                    =0.869).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions<\/jats:bold>\n                    : HIF-1\u03b1 expression, NLR, and PLR were not significantly associated with three-year progression-free survival in locally advanced CRC patients.\n                  <\/jats:p>","DOI":"10.3897\/folmed.68.e180500","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T09:22:42Z","timestamp":1786612962000},"source":"Crossref","is-referenced-by-count":0,"title":["The association of hypoxia-inducible factor-1 alpha expression, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio with three-year progression-free survival in locally advanced colorectal cancer patients"],"prefix":"10.3897","volume":"68","author":[{"given":"Galuh Chandra Kirana","family":"Sugianto","sequence":"first","affiliation":[{"name":"Hematology and Medical Oncology Division, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahmat","family":"Cahyanur","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology Division, Internal Medicine Department, Faculty of Medicine, University of Indonesia \u2013 Cipto Mangunkusumo General Hospital, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur","family":"Rahadiani","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, University of Indonesia \u2013 Cipto Mangunkusumo General Hospital, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleopas Martin","family":"Rumende","sequence":"additional","affiliation":[{"name":"Respirology and Critical Illness Division, Internal Medicine Department, Faculty of Medicine, University of Indonesia \u2013 Cipto Mangunkusumo General Hospital, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2258","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"180500_B1"},{"key":"180500_B2","doi-asserted-by":"crossref","unstructured":"Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Przegla\u031cd Gastroenterol 2019; 14(2):89\u2013103.","DOI":"10.5114\/pg.2018.81072"},{"key":"180500_B3","doi-asserted-by":"crossref","unstructured":"Roshandel G, Ghasemi-Kebria F, Malekzadeh R. Colorectal cancer: epidemiology, risk factors, and prevention. Cancers 2024; 16(8):1530.","DOI":"10.3390\/cancers16081530"},{"key":"180500_B4","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74(3):229\u201363.","DOI":"10.3322\/caac.21834"},{"key":"180500_B5","doi-asserted-by":"crossref","unstructured":"Scott AJ, Kennedy EB, Berlin J, et al. Management of locally advanced rectal cancer: ASCO guideline. J Clin Oncol 2024; 42(28):3355\u201375.","DOI":"10.1200\/JCO.24.01160"},{"key":"180500_B6","doi-asserted-by":"crossref","unstructured":"Whiteside T. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008 Oct 6;27(45):5904\u201312.","DOI":"10.1038\/onc.2008.271"},{"key":"180500_B7","doi-asserted-by":"crossref","unstructured":"Li J, Chen D, Shen M. Tumor microenvironment shapes colorectal cancer progression, metastasis, and treatment responses. Front Med [Internet] 2022 [cited 2024 Dec 26];9. Available from: https:\/\/www.frontiersin.org\/journals\/medicine\/articles\/10.3389\/fmed.2022.869010\/full","DOI":"10.3389\/fmed.2022.869010"},{"key":"180500_B8","doi-asserted-by":"crossref","unstructured":"Huang Y, Lin D, Taniguchi CM. Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe? Sci China Life Sci 2017; 60(10):1114\u201324.","DOI":"10.1007\/s11427-017-9178-y"},{"key":"180500_B9","doi-asserted-by":"crossref","unstructured":"Heshmat-Ghahdarijani K, Sarmadi V, Heidari A, et al. The neutrophil-to-lymphocyte ratio as a new prognostic factor in cancers: a narrative review. Front Oncol 2023; 13:1228076.","DOI":"10.3389\/fonc.2023.1228076"},{"key":"180500_B10","doi-asserted-by":"crossref","unstructured":"Tan D, Fu Y, Su Q, et al. Prognostic role of platelet\u2013lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Medicine (Baltimore) 2016; 95(24):e3837.","DOI":"10.1097\/MD.0000000000003837"},{"key":"180500_B11","doi-asserted-by":"crossref","unstructured":"Gyawali B, Eisenhauer E, Tregear M, et al. Progression-free survival: it is time for a new name. Lancet Oncol 2022; 23(3):328\u201330.","DOI":"10.1016\/S1470-2045(22)00015-8"},{"key":"180500_B12","doi-asserted-by":"crossref","unstructured":"Andr\u00e9 T, O\u2019Neil BH, Meyerhardt JA. Stage III colon cancer: what works, what doesn\u2019t and why, and what\u2019s next. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet 2012; 223\u201330.","DOI":"10.14694\/EdBook_AM.2012.32.39"},{"key":"180500_B13","doi-asserted-by":"crossref","unstructured":"Liu Q, Xi Y, He G, et al. Dynamics of neutrophil-to-lymphocyte ratio predict outcomes of metastatic colorectal carcinoma patients treated by FOLFOX. J Gastrointest Oncol 2021; 12(6):2846\u201353.","DOI":"10.21037\/jgo-21-716"},{"key":"180500_B14","doi-asserted-by":"crossref","unstructured":"Wei TT, Lin YT, Tang SP, et al. Metabolic targeting of HIF-1\u03b1 potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer. Oncogene 2020; 39(2):414\u201327.","DOI":"10.1038\/s41388-019-0999-8"},{"key":"180500_B15","doi-asserted-by":"crossref","unstructured":"Jia W, Yuan L, Ni H, et al. Prognostic value of platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and lymphocyte-to-white blood cell ratio in colorectal cancer patients who received neoadjuvant chemotherapy. Technol Cancer Res Treat 2021; 20:15330338211034291.","DOI":"10.1177\/15330338211034291"},{"key":"180500_B16","doi-asserted-by":"crossref","unstructured":"Chen Z, He X, Xia W, et al. Prognostic value and clinicopathological differences of HIFs in colorectal cancer: evidence from meta-analysis. PLoS ONE 2013; 8(12):e80337.","DOI":"10.1371\/journal.pone.0080337"},{"key":"180500_B17","doi-asserted-by":"crossref","unstructured":"Baba Y, Nosho K, Shima K, et al. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol 2010; 176(5):2292\u2013301.","DOI":"10.2353\/ajpath.2010.090972"},{"key":"180500_B18","doi-asserted-by":"crossref","unstructured":"Cao D, Hou M, Guan YS, et al. Expression of HIF-1 alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer 2009; 9(1):432.","DOI":"10.1186\/1471-2407-9-432"},{"key":"180500_B19","doi-asserted-by":"crossref","unstructured":"Liu S, Liu Y, Qiu X, et al. Tissue-of-origin for cancers determines HIF-1 activation induced phenotypic heterogeneity. Mol Carcinog 2024; 63(5):834\u201348.","DOI":"10.1002\/mc.23691"},{"key":"180500_B20","unstructured":"Harrison\u2019s principles of internal medicine. 21st ed. New York: McGraw Hill; 2022."},{"key":"180500_B21","doi-asserted-by":"crossref","unstructured":"Treatment of locally advanced\/metastatic colorectal cancer. J Natl Compr Canc Netw 2021; 19(5.5):617\u201321.","DOI":"10.6004\/jnccn.2021.5014"},{"key":"180500_B22","doi-asserted-by":"crossref","unstructured":"Ashique S, Bhowmick M, Pal R, et al. Multi drug resistance in colorectal cancer- approaches to overcome, advancements and future success. Adv Cancer Biol - Metastasis 2024; 10:100114.","DOI":"10.1016\/j.adcanc.2024.100114"},{"key":"180500_B23","doi-asserted-by":"crossref","unstructured":"Yang J, Guo X, Wu T, et al. Prognostic significance of inflammation-based indexes in patients with stage III\/IV colorectal cancer after adjuvant chemoradiotherapy. Medicine (Baltimore) 2019; 98(6):e14420.","DOI":"10.1097\/MD.0000000000014420"},{"key":"180500_B24","doi-asserted-by":"crossref","unstructured":"Chen L, Yang F, Chen S, et al. Mechanisms on chemotherapy resistance of colorectal cancer stem cells and research progress of reverse transformation: a mini-review. Front Med [Internet]. 2022 [cited 2025 Jan 25];9. Available from: https:\/\/www.frontiersin.org\/journals\/medicine\/articles\/10.3389\/fmed.2022.995882\/full","DOI":"10.3389\/fmed.2022.995882"},{"key":"180500_B25","doi-asserted-by":"crossref","unstructured":"Hwang K, Yoon JH, Lee JH, et al. Recent advances in monoclonal antibody therapy for colorectal cancers. Biomedicines 2021; 9(1):39.","DOI":"10.3390\/biomedicines9010039"},{"key":"180500_B26","doi-asserted-by":"crossref","unstructured":"Guo G, Hu X, Gao T, et al. Potential impact of platelet-to-lymphocyte ratio on prognosis in patients with colorectal cancer: a systematic review and meta-analysis. Front Surg 2023; 10:1139503.","DOI":"10.3389\/fsurg.2023.1139503"}],"container-title":["Folia Medica"],"original-title":[],"link":[{"URL":"https:\/\/foliamedica.bg\/article\/180500\/download\/pdf\/","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/foliamedica.bg\/article\/180500\/download\/xml\/","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/foliamedica.bg\/article_preview.php?id=180500&skip_redirect=1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T09:22:55Z","timestamp":1786612975000},"score":1,"resource":{"primary":{"URL":"https:\/\/foliamedica.bg\/article\/180500\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,13]]}},"URL":"https:\/\/doi.org\/10.3897\/folmed.68.e180500","relation":{},"ISSN":["1314-2143","0204-8043"],"issn-type":[{"value":"1314-2143","type":"electronic"},{"value":"0204-8043","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"article-number":"e180500"}}